Evaluation of respiratory syncytial virus vaccines in infants and pregnant women
Summary
Ontario introduced in the fall of 2024 a new immunization program, Nirsevimab (NSVB), for the prevention of RSV infection in infants. Unlike the previous program which targeted only high-risk infants, this monoclonal is offered to all infants in the first year of life. We will investigate the uptake of nirsevimab and sociodemographic factors associated with the uptake.
Knowledge User
Office of the CMOH; MOH
Information
Project ID
2024-048/ 2025 0950 189 000
Contributing ICES Scientists
Type of Response
Status
AHRQ Project
2025
A request from an Indigenous community or organization has been accepted
Project ID: 2025-030/2026 0950 208 000
Project Year: 2025
Status: In progress
AHRQ Project
2025
Ontario Osteoporosis Strategy Management & Evaluation (OOS-ME)
Project ID: 2025-008/2026 0900 819 004
Project Year: 2025
ICES Scientist: Suzanne Cadarette
Status: In progress